pyrazines has been researched along with carbostyril in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashida, W; Kawai, C; Kumada, T | 1 |
| Feldman, AM; Strobeck, JE | 1 |
| Young, JB | 1 |
| Bertolet, BD | 1 |
| Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
| Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N | 1 |
| Armand, JP; Burnett, AK; Drach, J; Harousseau, JL; Löwenberg, B; San Miguel, J | 1 |
| Bonnefous, C; Chen, X; Hassig, CA; Nguyen, PM; Noble, SA; Payne, JE; Rao, TS; Rix, P; Roppe, J; Rozenkrants, N; Sablad, M; Severance, D; Shiau, AK; Smith, ND; Symons, KT; Walsh, JP; Wang, L; Yazdani, N; Zhang, Y; Zhuang, H | 1 |
| Boise, LH; Chen, J; David, E; Flowers, CR; Kaufman, JL; Lonial, S; Marcus, AI; Schafer-Hales, K; Sun, SY; Torre, C | 1 |
| Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S | 1 |
| Piao, HR; Wu, Y | 1 |
| Batra, SK; Dhanasingh, I; Kanteti, R; Kaushik, G; Kindler, HL; Kulkarni, P; Mambetsariev, B; Mirzapoiazova, T; Nasser, MW; Ponnusamy, MP; Riehm, JJ; Salgia, R; Seshacharyulu, P; Wang, J | 1 |
| De Koning, L; De Wolf, J; Jaurand, MC; Jean, D; Le Pimpec-Barthes, F; Meiller, C; Montagne, F; Quetel, L; Tranchant, R; Zucman-Rossi, J | 1 |
| Xia, X | 1 |
5 review(s) available for pyrazines and carbostyril
| Article | Year |
|---|---|
[New oral drugs for the treatment of congestive heart failure].
Topics: Administration, Oral; Cardiotonic Agents; Deoxyepinephrine; Ethanolamines; Heart Failure; Humans; Phosphodiesterase Inhibitors; Piperidines; Propanolamines; Pyrazines; Quinolines; Quinolones; Vasodilator Agents; Xamoterol | 1992 |
Quinolinone derivatives in the management of congestive heart failure.
Topics: Animals; Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines; Quinolones | 1994 |
Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Topics: Animals; Clinical Trials as Topic; Death, Sudden; Heart Failure; Humans; Monitoring, Physiologic; Multicenter Studies as Topic; Neutropenia; Pyrazines; Quinolines; Quinolones | 2004 |
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hematologic Neoplasms; Humans; Pyrazines; Quinolones | 2007 |
The progress towards the development of DHQO derivatives and related analogues with inotropic effects.
Topics: Animals; Cardiotonic Agents; Pyrazines; Quinolines; Quinolones; Rabbits; Stroke Volume; Structure-Activity Relationship | 2013 |
1 trial(s) available for pyrazines and carbostyril
| Article | Year |
|---|---|
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones | 2011 |
9 other study(ies) available for pyrazines and carbostyril
| Article | Year |
|---|---|
The best of times, the worst of times: the wealth and poverty of heart failure pharmacotherapies: is there a role for vesnarinone?
Topics: Clinical Trials as Topic; Drug Therapy; Forecasting; Heart Failure; Humans; Pyrazines; Quinolines; Quinolones; Socioeconomic Factors; Time Factors | 2004 |
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured | 2006 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models.
Topics: Administration, Oral; Animals; Cell Line; Constriction, Pathologic; Disease Models, Animal; Drug Discovery; Enzyme Inhibitors; Fluoroquinolones; Formaldehyde; Humans; Inhibitory Concentration 50; Lipopolysaccharides; Mice; Nitric Oxide Synthase Type II; Pain; Protein Multimerization; Protein Structure, Quaternary; Pyrazines; Quinolones; Structure-Activity Relationship; Substrate Specificity | 2009 |
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Quinolones; Ubiquitination | 2010 |
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; Pleural Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinolones; Sulfonamides; Sulfones | 2018 |
Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Phenols; Pleural Neoplasms; Pyrazines; Quinolones; RNA Interference; Signal Transduction; Sulfonamides; Tumor Cells, Cultured; Verteporfin | 2018 |
Drug efficacy and toxicity prediction: an innovative application of transcriptomic data.
Topics: Aminophenols; Aminopyridines; Animals; Antineoplastic Agents; Benzodioxoles; Cell Death; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Combinations; Drug Development; Epithelial Cells; Gene Expression Profiling; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyrazoles; Quinolones; Toxicity Tests; Transcriptome | 2020 |